• Investors may be asking whether Centene's current share price reflects its true worth, or if the recent weakness could be setting up a more interesting entry point.
• Centene's stock closed at US$41.09, with a 5.4% gain over the last 7 days and a 24.6% gain over the last 30 days, while returns sit at a 1.7% decline year to date and a 33.3% decline over the past year.
• Recent news around Centene has focused on its position in managed care and healthcare services, as investors weigh how policy, reimbursement trends, and competitive dynamics might influence the business. This backdrop helps frame why the share price has shown both strong short term moves and weaker longer term returns.
• Centene currently holds a valuation score of 5/6. The next sections will compare how different valuation methods line up with that score and will also point you to an additional way to think about valuation at the end of the article.

Approach 1: Centene Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and then discounting those cash flows back to a present value.

For Centene, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s last twelve months Free Cash Flow is about $4.25b. Analyst inputs and extrapolated estimates point to projected Free Cash Flow of $3.92b by 2030, with a series of yearly projections between 2026 and 2035 that are discounted back to today using Simply Wall St’s assumptions.

Putting these discounted cash flows together produces an estimated intrinsic value of US$201.45 per share. Compared to the recent share price of US$41.09, the DCF output suggests the stock is 79.6% undervalued on this set of assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Centene is undervalued by 79.6%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: Centene Price vs Sales

For established, revenue generating healthcare companies, the Price to Sales, or P/S, ratio is a useful cross check because it compares what the market is paying for each dollar of revenue rather than relying on earnings, which can be affected by one off items or margins in any single period.

Growth expectations and risk still matter here, because investors typically accept a higher “normal” P/S ratio for companies where they see stronger revenue growth potential and lower perceived risk, and a lower P/S where growth is expected to be more modest or risks are higher.

Centene currently trades on a P/S ratio of 0.11x. This sits well below the Healthcare industry average P/S of 1.16x and the peer group average of 1.45x. Simply Wall St’s Fair Ratio for Centene is 0.71x, which reflects a tailored view of what the P/S could be given factors such as the company’s earnings growth profile, industry, profit margin, market cap and specific risks.

This Fair Ratio is more informative than a simple comparison with peers or the industry, because it adjusts for Centene’s own growth, risk and profitability rather than assuming all healthcare stocks deserve the same multiple. Compared with the actual P/S of 0.11x, the Fair Ratio of 0.71x suggests the shares trade below that customised reference point.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Centene Narrative

Earlier this article alluded to a better way to think about valuation, and Narratives are that tool. They let you set out a clear story for Centene that ties your view of its business to explicit forecasts for future revenue, earnings and margins. These then flow into a fair value that you can compare with the current price to decide whether it looks attractive or not. All of this happens within Simply Wall St’s Community page, where Narratives update automatically when new news or earnings arrive. One investor might build a cautious Centene Narrative that lines up with a Fair Value near US$26.83, while another uses a more optimistic Centene Narrative aligned with Fair Value around US$60.51. Both can quickly see how their story, numbers and fair value differ without needing complex spreadsheets.

For Centene however we will make it really easy for you with previews of two leading Centene Narratives:

Fair value: US$95.24 per share

Implied discount to fair value: 56.9% compared to the last close

Revenue growth assumption: 4%

• Frames Centene as a leading Medicaid and Affordable Care Act insurer that has faced higher medical costs and a sharp share price pullback, with a view that the reaction may have been too harsh.
• Highlights potential drivers such as 2026 ACA premium adjustments across multiple states, new Medicaid contracts with improved rates, and an approved US$2,000m share repurchase program.
• Flags key risks around elevated medical loss ratios, possible subsidy cuts, and regulatory fines, with a focus on adjusting exposure based on how upcoming results and medical costs develop.

Fair value: US$32.00 per share

Implied downside to fair value: 28.5% overvalued compared to the last close

Revenue growth assumption: 1.94%

• Emphasizes regulatory scrutiny, changing Medicaid and Marketplace membership patterns, and operational complexity as factors that could pressure margins and keep profitability under strain.
• Builds in assumptions for modest revenue growth, much lower profit margins and earnings by 2028, and a higher future P/E multiple to align with the most cautious analyst price target of US$24.00.
• Points out that analyst views vary widely, and encourages you to test the bearish assumptions on revenue, earnings and valuation against your own expectations for Centene.

If you want to see how other investors connect these types of assumptions to fair values and risk assessments for Centene, you can review the full community narratives alongside your own work using See what the community is saying about Centene.

Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.